http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2019011494-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4fede5e271fe9a3788b900c0ce6e0054
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6801
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6889
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
filingDate 2016-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc6fbb59c39844631a6bec213e2c9a8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_86e55884817b490b1a8ee6fab0b256ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b021f4d309e7c8bb77e8a0bafd0f2f56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a0f0f7613e91194dbc965e654d77d93
publicationDate 2019-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber MX-2019011494-A
titleOfInvention DUOCARMICIN ANTIBODY-DRUG CONJUGATES (ADC) SHOWING IMPROVED IN VIVO ANTITUMORAL ACTIVITY.
abstract The present invention relates to antibody-drug conjugates (ADC) containing duocarmycin for use in the treatment of HER2-expressing human solid tumors and hematological malignancies, in particular breast cancer, gastric cancer, bladder cancer, cancer of the ovarian, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, squamous cell cancer of the head and neck or osteosarcoma and acute lymphoblastic leukemia; in particular, the present invention relates to ADCs containing duocarmycin for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ tissue status and negative for HER2 FISH; Advantageously, the present invention relates to ADCs containing duocarmycin for use in the treatment of triply negative breast cancer (TNBC).
priorityDate 2014-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID115369
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415817004

Total number of triples: 45.